SCHEMBL7000461

SCHEMBL7000461

Oc1cccnc1CC(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 5/20 0.49
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.45
CHRM1 P11229 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
MMP2 P08253 1/20 0.39
TSHR P16473 1/20 0.39
COMT P21964 1/20 0.39
ADRA1A P35348 1/20 0.39
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
KDM1A O60341 1/20 0.39
HCRTR1 O43613 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12870191 0.80 ALDH1A1 (0.59) L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A
SCHEMBL22719069 0.78 KDM1A (0.40) L3MBTL1ALDH1A1KDM4EKDM1AHCRTR1
SCHEMBL95140 0.77 ALDH1A1 (0.55) L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A
SCHEMBL20818377 0.77 L3MBTL1 (0.46) L3MBTL1ALDH1A1KDM4EHSD17B10TSHR
SCHEMBL22719100 0.76 HDAC1 (0.39) L3MBTL1ALDH1A1HCRTR1HCRTR2KMT2A
SCHEMBL17784620 0.74 NAPRT (0.53) L3MBTL1ALDH1A1KDM4EHIF1ATSHR
SCHEMBL1179397 0.74
SCHEMBL30463155 0.74
SCHEMBL20818541 0.73 DPP4 (0.40) L3MBTL1ALDH1A1HCRTR1HCRTR2
SCHEMBL20818450 0.73 ALDH1A1 (0.33) L3MBTL1ALDH1A1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030158245-A1 Fused heterocyclic derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-21 US disclosed
EP-1268486-A2 FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed
WO-2001074823-A2 FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158245-A1 Fused heterocyclic derivatives, their production and use TST, STS, AHR L3MBTL1 2518/4885ALDH1A1 327/4885KDM4E 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.